Sage Therapeutics Inc.’s recently made public that its Director JONAS JEFFREY M unloaded Company’s shares for reported $0.52 million on Feb 10. In the deal valued at $44.61 per share,11,643 shares were sold. As a result of this transaction, JONAS JEFFREY M now holds 121,981 shares worth roughly $ 4.83 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Then, Greene Barry E bought 14,500 shares, generating $500,022 in total proceeds. Upon buying the shares at $34.48, the President and CEO now owns 46,940 shares.
Before that, Golumbeski George bought 8,000 shares. Sage Therapeutics Inc. shares valued at $251,563 were divested by the Director at a price of $31.45 per share. As a result of the transaction, Golumbeski George now holds 8,000 shares, worth roughly $0.32 million.
Guggenheim downgraded its Sage Therapeutics Inc. [SAGE] rating to a Neutral from a a Buy in a research note published on Friday. A number of analysts have revised their coverage, including Loop Capital’s analysts, who began to cover the stock in early November with a ‘”a Hold”‘ rating. Berenberg began covering SAGE with “Hold” recommendation on March 31, 2022. Guggenheim revised its rating on November 02, 2021. It rated SAGE as “a Buy” which previously was an “a Neutral”.
Price Performance Review of SAGE
On Friday, Sage Therapeutics Inc. [NASDAQ:SAGE] saw its stock fall -8.15% to $39.56. On the same session, the stock had its day’s lowest price of $38.665, but rose to a high of $42.96. Over the last five days, the stock has lost -5.34%. Sage Therapeutics Inc. shares have risen nearly 3.72% since the year began. Nevertheless, the stocks have risen 20.72% over the past one year. While a 52-week high of $49.56 was reached on 01/13/23, a 52-week low of $27.36 was recorded on 01/03/23. SMA at 50 days reached $42.71, while 200 days put it at $38.92. A total of 1.06 million shares were traded, compared to the trading of 0.7 million shares in the previous session.
Levels Of Support And Resistance For SAGE Stock
The 24-hour chart illustrates a support level at 37.83, which if violated will result in even more drops to 36.10. On the upside, there is a resistance level at 42.13. A further resistance level may holdings at 44.69. The Relative Strength Index (RSI) on the 14-day chart is 39.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.93%. Stochastics %K at 47.91% indicates the stock is a holding.
How much short interest is there in Sage Therapeutics Inc.?
A steep rise in short interest was recorded in Sage Therapeutics Inc. stocks on Jan 12, 2023, dropping by -0.25 million shares to a total of 3.83 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 4.08 million shares. There was a decline of -6.53%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.52% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.94.
Sage Therapeutics Inc. [SAGE] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 6,551,268 shares, or roughly 10.97% of the outstanding SAGE shares. In other words, the investor’s shares have risen by 233,754 from its previous 13-F filing of 6317514.0. Additionally, Wellington Management Co. LLP increased 11.83% of its stake after which the total value it holdings stand at $229,691,903, while The Vanguard Group, Inc. added 1.90% of its stake to hold $199.5 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 81,478 shares of Sage Therapeutics Inc., while Bellevue Asset Management AG bought 131,000 shares. At present, SSgA Funds Management, Inc. is holding 2,727,296 shares valued at $113.56 million. T. Rowe Price Associates, Inc. owned 1,897,322 shares of the company at the time of its most recent 13F filing, worth $79.0 million.
According to FactSet, Sage Therapeutics Inc.’s share price will average $56.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 16.09 percent from its previous closing price of $43.07. Analysts expect Sage Therapeutics Inc. stock to reach the higher price of $105.00, while the lowest price estimate is $36.00. However, 23 analysts have rated SAGE stock as an Overweight in their predictions for 2023.